HC Wainwright Equities Analysts Increase Earnings Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI)

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at HC Wainwright lifted their FY2027 EPS estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.99 for the year, up from their prior estimate of $1.94. HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2028 earnings at $4.48 EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the prior year, the company earned ($0.80) EPS.

A number of other research firms also recently issued reports on DNLI. Stifel Nicolaus reduced their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday. Wedbush decreased their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday. The Goldman Sachs Group dropped their price objective on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Finally, UBS Group decreased their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.22.

Denali Therapeutics Trading Up 12.2 %

Shares of NASDAQ:DNLI opened at $18.90 on Thursday. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -17.50 and a beta of 1.39. The business has a 50-day moving average price of $18.80 and a 200 day moving average price of $18.84. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.31.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the sale, the director now directly owns 121,375 shares in the company, valued at approximately $2,229,658.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Denali Therapeutics news, insider Carole Ho sold 2,784 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $48,135.36. Following the transaction, the insider now directly owns 145,010 shares of the company’s stock, valued at approximately $2,507,222.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the sale, the director now directly owns 121,375 shares of the company’s stock, valued at $2,229,658.75. The disclosure for this sale can be found here. Insiders have sold a total of 110,955 shares of company stock worth $2,218,802 over the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. Edmond DE Rothschild Holding S.A. lifted its holdings in shares of Denali Therapeutics by 24.1% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 205,680 shares of the company’s stock worth $4,221,000 after purchasing an additional 40,000 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Denali Therapeutics by 9.9% in the first quarter. ProShare Advisors LLC now owns 31,205 shares of the company’s stock valued at $640,000 after acquiring an additional 2,820 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics during the first quarter worth about $88,000. Susquehanna Fundamental Investments LLC purchased a new position in Denali Therapeutics during the first quarter worth about $4,330,000. Finally, Swiss National Bank increased its position in Denali Therapeutics by 0.7% during the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock worth $4,477,000 after purchasing an additional 1,500 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.